69.78
0.11%
-0.08
After Hours:
69.78
Edwards Lifesciences Corp stock is traded at $69.78, with a volume of 4.93M.
It is down -0.11% in the last 24 hours and down -5.86% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
See More
Previous Close:
$69.86
Open:
$69.96
24h Volume:
4.93M
Relative Volume:
1.06
Market Cap:
$41.16B
Revenue:
$6.60B
Net Income/Loss:
$4.16B
P/E Ratio:
10.07
EPS:
6.93
Net Cash Flow:
$490.10M
1W Performance:
-4.96%
1M Performance:
-5.86%
6M Performance:
-20.08%
1Y Performance:
-5.47%
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
Jul-25-24 | Downgrade | Truist | Buy → Hold |
May-30-24 | Initiated | Goldman | Buy |
May-22-24 | Upgrade | Citigroup | Neutral → Buy |
May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
May-30-23 | Resumed | Morgan Stanley | Overweight |
Mar-29-23 | Initiated | UBS | Neutral |
Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-06-22 | Downgrade | Stifel | Buy → Hold |
Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
Oct-26-22 | Initiated | Mizuho | Buy |
Oct-18-22 | Initiated | Barclays | Overweight |
Oct-12-22 | Initiated | Jefferies | Buy |
Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
Apr-13-22 | Initiated | Truist | Buy |
Apr-06-22 | Initiated | Wolfe Research | Outperform |
Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Mar-02-22 | Resumed | BofA Securities | Neutral |
Feb-02-22 | Upgrade | UBS | Neutral → Buy |
Jan-27-22 | Reiterated | Citigroup | Buy |
Jan-27-22 | Reiterated | Evercore ISI | Outperform |
Jan-27-22 | Reiterated | Raymond James | Outperform |
Jan-27-22 | Reiterated | Stifel | Buy |
Jan-27-22 | Reiterated | UBS | Neutral |
Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
Jul-30-21 | Reiterated | Deutsche Bank | Hold |
Jul-30-21 | Reiterated | Jefferies | Buy |
Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
Jul-30-21 | Reiterated | Oppenheimer | Outperform |
Jul-30-21 | Reiterated | Stifel | Buy |
Jul-30-21 | Reiterated | UBS | Neutral |
Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
May-25-21 | Initiated | Barclays | Overweight |
Apr-15-21 | Initiated | Atlantic Equities | Neutral |
Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
Sep-11-20 | Initiated | Wolfe Research | Underperform |
Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-13-20 | Initiated | Goldman | Neutral |
Feb-06-20 | Resumed | BTIG Research | Neutral |
Jan-10-20 | Initiated | Oppenheimer | Outperform |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
Sep-23-19 | Initiated | Piper Jaffray | Overweight |
Jul-24-19 | Reiterated | BofA/Merrill | Buy |
Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Jan-03-19 | Initiated | Deutsche Bank | Hold |
Nov-28-18 | Initiated | UBS | Neutral |
Oct-16-18 | Initiated | Barclays | Underweight |
Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock - MSN
Seilern Investment Management Ltd Invests $109.49 Million in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Gateway Investment Advisers LLC Acquires 5,726 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Sees Significant Growth in Short Interest - MarketBeat
Boston Common Asset Management LLC Lowers Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
65,442 Shares in Edwards Lifesciences Co. (NYSE:EW) Purchased by Avanza Fonder AB - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) VP Sells $34,380.00 in Stock - MarketBeat
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock By Investing.com - Investing.com Canada
Wolfe Research Downgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences exec sells $343,735 in stock - Investing.com
Do You Believe in the Growth Prospects of Edwards Lifesciences Corporation (EW)? - MSN
West Coast Financial LLC Sells 9,846 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Wolfe Research cuts Edwards Lifesciences stock rating to Underperform - MSN
Wolfe Research Downgrades Edwards Lifesciences (NYSE:EW) to Underperform - MarketBeat
Should Edwards Lifesciences Stock Stay in Your Portfolio Now? - Yahoo Finance
Meril successful at EPO against Edwards Lifesciences in heart-valve battle - JUVE Patent
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Assenagon Asset Management S.A. Buys 3,506,886 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST Purchases 300,000 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences price target raised to $74 from $72 at Bernstein - MSN
Edwards Lifesciences’ Q4 2024 Earnings: What to Expect - Nasdaq
Edwards Lifesciences’ Q4 2024 Earnings: What To Expect - Barchart
Edwards Lifesciences Co. (NYSE:EW) Receives $79.40 Consensus Target Price from Analysts - MarketBeat
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Stock Price | EW Stock Quote, News, and History - Markets Insider
Brain Ischemia Market grow at CAGR of 7.6% Growth, Reaching $1,622 million by 2032 Globally - GlobeNewswire Inc.
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Nordea Investment Management AB Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) is largely controlled by institutional shareholders who own 85% of the company - Yahoo Finance
Edwards Lifesciences price target raised to $75 from $69 at Evercore ISI - Yahoo Finance
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Share Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Edwards Lifesciences gets FDA warning letter - Reuters
Edwards Lifesciences Corporation (EW): Among the Cheap Healthcare Stocks to Buy Heading Into 2025 - Insider Monkey
Edwards Lifesciences Corp. stock rises Tuesday, still underperforms market - MarketWatch
Wolfe Research Upgrades Edwards Lifesciences (EW) - MSN
Edwards Lifesciences Corp. stock remains steady Monday, underperforms market - MarketWatch
Principal Financial Group Inc. Has $53.95 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Corporation's (NYSE:EW) Price Is Out Of Tune With Earnings - Simply Wall St
Jim Cramer: Is Edwards Lifesciences (EW) Poised for a Comeback? - Insider Monkey
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
EDWARDS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Edwards lifesciences CVP Daniel Lippis sells $185k in stock By Investing.com - Investing.com Australia
Edwards Lifesciences' SWOT analysis: stock outlook amid TAVR challenges and TMTT growth - Investing.com
Edwards lifesciences CVP Daniel Lippis sells $185k in stock - Investing.com India
Daniel J. Lippis Sells 2,500 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock - MarketBeat
Assessing Edwards Lifesciences: Insights From 20 Financial Analysts - Benzinga
Edwards Lifesciences shares upgraded to buy, target lifted on trajectory - Investing.com
Bank of America Upgrades Edwards Lifesciences (NYSE:EW) to "Buy" - MarketBeat
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):